Zealand Pharma

News

Zealand hit as Roche-partnered obesity drug disappoints

Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.

News

Measuring tape overlain on a dark yellow background

Pfizer's $2bn+ obesity bet, and other weight-loss news

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

Ironwood crashes down as FDA seeks new phase 3 trial

Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide.

News

Roche builds in obesity with $5.3bn Zealand licensing deal

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.

News

FDA knocks back Zealand's dasiglucagon once again

Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market.

News

David Kendall, chief medical officer at Zealand Pharma

Zealand Pharma rakes in $1bn in funding for obesity drugs

Fresh from reporting encouraging results with its obesity drug candidate petrelintide, Zealand Pharma has raised an impressive $1 billion from a new share offering.

Zealand hit as Roche-partnered obesity drug disappoints

Pfizer's $2bn+ obesity bet, and other weight-loss news

Ironwood crashes down as FDA seeks new phase 3 trial

Roche builds in obesity with $5.3bn Zealand licensing deal

FDA knocks back Zealand's dasiglucagon once again

Zealand Pharma rakes in $1bn in funding for obesity drugs

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

Zealand Pharma

Editor's Picks